Inhibition of CDK8/19 Mediator kinases, pleiotropic regulators of transcriptional reprogramming, inhibits the growth of TNBC tumors, extends the survival of metastatic disease, and strongly enhances tumor suppression by targeted drugs in vivo, suggesting that CDK8/19 inhibitors may achieve a transformative impact on TNBC therapy. This evidence concerns the gene CDK8 and neoplasm.